| abstract |
Disclosed herein are substituted tricyclic benzimidazole compounds as defined by formula (I), or a pharmaceutically acceptable salt thereof. The compounds of the present invention selectively inhibit CDK8 and are therefore useful for treating diseases associated with this kinase, particularly colorectal and melanoma cancers and other solid and hematological malignancies, autoimmune diseases and inflammatory diseases. Methods for making these compounds are also disclosed. (I) |